VPC-3033
VPC-3033 is an androgen receptor antagonist. VPC-3033 has a strong androgen DHT replacement potency (IC50: 0.625-2.5 μM), can effectively inhibit androgen receptor transcriptional activity (IC50=0.3 μM), and has a strong androgen receptor degradation ability. In addition, VPC-3033 exhibits significant anti-androgen receptor activity against prostate cancer cells resistant to Enzalutamide.
Product Specifications
CAS Number
110763-24-1
UNSPSC
12352005
Target
Androgen Receptor
Type
Reference compound
Related Pathways
Vitamin D Related/Nuclear Receptor
Field of Research
Cancer; Endocrinology
Assay Protocol
https://www.medchemexpress.com/vpc-3033.html
Smiles
O=C1C2=C(/C(C3=C1C=CC=C3)=C\C4=CC(O)=CC=C4)C=CC=C2
Molecular Formula
C21H14O2
Molecular Weight
298.33
References & Citations
[1]Li H, et al. Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer[J]. Molecular cancer therapeutics, 2013, 12 (11) : 2425-2435.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC471741-500 1x 500 µL
Epstein-Barr Virus (LMP-1) (CS1), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
LC433077 20 µg
RepuLsive Guidance MolecuLe A (RGMA) (NM_001166287) Human Over-expression Lysate
Sign In for Pricing
View Details